Skip to main content

Table 2 Number of cancer cases among subjects that subsequently became digitoxin users.

From: Digitoxin medication and cancer; case control and internal dose-response studies

ICD-10 Site Sex Digitoxin group Control group Odds Ratio (95% CI)
C50 Breast F 275 232 1.19(1.11, 1.28)
C61 Prostate M 370 296 1.25(1.08, 1.45)
C18–21 Colo-rectal M+F 430 325 1.32(1.15, 1.52)
C32–34 Lung M+F 163 112 1.46(1.15, 1.86)
C64,C65,C67,C68 Kidney, urinary M+F 201 180 1.06(0.95, 1.17)
C43.C44 Melanoma, other skin M+F 154 191 0.81 (0.66, 0.99)
C81–C85,C88– Leukemia/Lymphoma M+F 198 117 1.69(1.35,2.11)
C92      
C00–C97 All sites M+F 2435 2017 1.21 (1.15, 1.28)
  1. Number of cancer cases among subjects that subsequently became digitoxin users,and among matched controls.Digitoxin group=the cancer cases among the 9271 patients constituting the database just before the start on digitoxin medication. Control group=for each subject in the digitoxin group one control was randomly picked out from the general population. These controls were matched on birthday and gender and should be alive at the time when the corresponding digitoxin user started on digitoxin.